Zacks Investment Research cut shares of Synthetic Biologics Inc (NYSEMKT:SYN) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning.

According to Zacks, “Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan. “

Separately, ValuEngine downgraded Synthetic Biologics from a sell rating to a strong sell rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The company has an average rating of Hold and an average price target of $3.92.

Synthetic Biologics (NYSEMKT:SYN) traded down 0.581% during trading on Tuesday, reaching $0.856. The company’s stock had a trading volume of 270,275 shares. Synthetic Biologics has a 52-week low of $0.41 and a 52-week high of $1.74. The stock’s market cap is $109.78 million. The firm has a 50 day moving average price of $0.82 and a 200-day moving average price of $0.63.

Synthetic Biologics (NYSEMKT:SYN) last announced its earnings results on Thursday, August 3rd. The company reported ($0.03) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.03. On average, analysts expect that Synthetic Biologics will post ($0.17) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at

Several large investors have recently made changes to their positions in SYN. Bank of New York Mellon Corp lifted its stake in shares of Synthetic Biologics by 3.1% in the 1st quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after purchasing an additional 7,962 shares during the period. UBS Group AG raised its stake in Synthetic Biologics by 10.3% during the 1st quarter. UBS Group AG now owns 214,357 shares of the company’s stock worth $135,000 after buying an additional 20,038 shares during the period. Creative Planning raised its stake in Synthetic Biologics by 65.4% during the 2nd quarter. Creative Planning now owns 177,000 shares of the company’s stock worth $100,000 after buying an additional 70,000 shares during the period. LMR Partners LLP acquired a new position in Synthetic Biologics during the 2nd quarter worth approximately $194,000. Finally, Goldman Sachs Group Inc. raised its stake in Synthetic Biologics by 8,102.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,129,108 shares of the company’s stock worth $639,000 after buying an additional 1,115,343 shares during the period.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Stock Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related stocks with our FREE daily email newsletter.